A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Iptacopan (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms APPLAUSE; APPLAUSE-IgAN
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Aug 2024 According to a Novartis media release, the company receives FDA accelerated approval for Fabhalta (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
- 25 May 2024 According to a Novartis media release, the 9-month interim analysis data to be presenting at European Renal Association (ERA) Congress.
- 14 May 2024 According to National Kidney Foundation Media Release, data from this study will be presented tomorrow at 2024 NKF Spring Clinical Meetings (SCM)